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OBJECTIVE—The pathogenesis of painful diabetic neuropathy (DN) remains undetermined,
with both central and peripheral mechanisms implicated. This study investigates whether tha-
lamic perfusion abnormalities occur in painful DN.
RESEARCH DESIGN AND METHODS—Eighteen subjects with type 1 diabetes
(no DN = 6, painful DN = 5, painless DN = 7) and six healthy volunteers (HV) were recruited.
Microvascular perfusion characteristics (relative cerebral blood volume [rCBV], ﬂow [rCBF],
and transit time [ttFM]) of the thalamus and caudate nucleus were assessed using magnetic
resonance perfusion imaging. The caudate nucleus was chosen to serve as an in vivo control
region.
RESULTS—Subjects with painful DN had signiﬁcantly greater thalamic rCBV (means [SD];
painful DN, 228.7 [19.5]; no DN, 202.3 [25.8]; painless DN, 216.5 [65.5]; HV, 181.9 [51.7];
P = 0.04) and the longest ttFM(s) (painful DN, 38.4 [3.6]; no DN, 35.3 [13.2]; painless DN, 35.9
[13.7]; HV, 33.7 [14.9]; P = 0.07). There was no signiﬁcant difference in markers of caudate
nucleus perfusion.
CONCLUSIONS—Painful DN is associated with increased thalamic vascularity. This may
provide an important clue to the pathogenesis of pain in DN.
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D iabetic neuropathy (DN) results inchronic painful symptoms that canaffect quality of life immensely (1).
We previously reported thalamic neuro-
nal dysfunction in subjects with painless
DN but not painful DN (2). The aim of
this study was to assess thalamic micro-
vascular perfusion characteristics in DN.
RESEARCH DESIGN AND
METHODS—Eighteen right-handed
men with type 1 diabetes were recruited.
Exclusion criteria were as follows: clini-
cally signiﬁcant systemic diseases, alcohol
consumption (.20 units/day), neuropa-
thies other than DN, hypoglycemia in the
preceding 24 h, and standardmagnetic res-
onance (MR)exclusioncriteria.Medications
that could alter cerebrovascular perfusion
were omitted. Subjects with painful DN
(NTSS 6 Score.4 and,16) (3) had symp-
toms for at least 6 months and were on
stable pain medications. Six age- and sex-
matched nondiabetic healthy volunteers
(HV) were also recruited. All subjects gave
written informed consent, and the study
had ethical approval.
Assessment of neuropathy
Clinical and neurophysiological assess-
ments were undertaken (4,5,6) to provide
a neuropathy composite score (NCS)
based on the neuropathy impairment
score of the lower limbs plus seven tests
(NIS[LL]+7) as described previously (7).
Subjects were divided into the following
groups: 1) no DN (asymptomatic subjects
with normal NCS, 2) painless DN (pain-
free subjects with both clinical and at least
two abnormalities of neurophysiologic
assessment), and 3) painful DN (painful
symptoms together with clinical and neu-
rophysiological abnormalities).
MR perfusion protocol
Examinations were performed on a 1.5-T
system (Eclipse, Philips Medical Sys-
tems). Cerebral perfusion was assessed
using a multitime point, single shot T2*
weighted echo-planar imaging (EPI) se-
quence (TEeff = 60 ms; TR = 1.4 s; acqui-
sition matrix = 192 3 188, zero-ﬁlled
before Fourier transformation to 256 3
256; ﬁeld of view (FOV) = 25 cm). Exog-
enous perfusion contrast was provided
by a 20-mL bolus of gadolinium diethy-
lenetriamine pentaacetic acid (Gd-DTPA;
Magnevist, Schering AG, Germany),
which was followed by a 20-mL saline
ﬂush, administered intravenously at a
rate of 5 mL/s.
The microvascular perfusion charac-
teristics of the thalamus (plays a central role
in modulating/processing nociceptive in-
formation) (8) and the caudate nucleus
were assessed. The caudate nucleus was
chosen as a control region since it is not
involved in somotosensory perception (9).
The following hemodynamic markers
of cerebral perfusion were calculated: 1)
relative cerebral blood volume (rCBV),
the volume of blood per unit time passing
through a region of brain tissue relative
proximal internal carotid artery ﬂow; 2)
ﬁrst moment transit time (TTFM, in sec-
onds), the average time for contrast bolus
to pass through a region of brain tissue;
and 3) relative cerebral blood ﬂow
(rCBF), the average volume of blood per
unit time (rCBV:TTFM) (10).
Statistical analysis
Analyses were performed using SPSS
14.0. Appropriate tests for normality were
conducted to guide subsequent analysis.
Subgroup demographics were compared
using one-way ANOVA and perfusion
markers using nonparametric tests.
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RESULTS—Subjects with painful DN
(62.0 [3.9]) were signiﬁcantly older than
those with no DN (44.9 [7.1]) and HV
(45.8 [14.7]; P = 0.03; painful DN vs. no
DN, P = 0.005, 95% CI 5.7–28.5; painful
DN vs. HV, P = 0.01, 95% CI 3.8–28.5).
Subjects were matched for BMI (HV 26.7
[5.2], no DN 30.2 [3.9], painless DN 25.6
[2.3], painful DN 31.1 [5.1]; P = 0.08)
and HbA1c (no DN 8.4 [0.2]), painless
DN 8.9 [0.9], and painful DN 7.7 [0.9];
P = 0.71). Subjects with painful DN (NCS
31.0 [9.5]) and painless DN (21.8 [15.5])
had comparable severity of neuropathy,
which were greater than those with no
DN (1.0 [1.1]). There was no difference
in the presence of microvascular compli-
cations (diabetic retinopathy data from
retinal screening database; painful DN
[n = 3], painless DN [n = 2], no DN
[n = 2], and diabetic nephropathy based
on albumin:creatinine ratio; painful DN
[n = 3], painless DN [n = 3], no DN [n = 1])
between subjects.
Figure 1 is a composite time proﬁle of
thalamic perfusion of the study groups.
The bolus arrival time (in seconds) was
delayed in both neuropathy subgroups
(painful DN 28.6 [1.6] and painless DN
27.3 [2.4]) compared with HV 23.6 (6.3)
and no DN 24.2 (5.9), P = 0.7, x2 = 1.3.
Overall group comparison showed that
subjects with painful DN (rCBV 228.7
[19.5]) have the tallest peak concentra-
tion of Gd-DTPA and signiﬁcantly greater
mean thalamic rCBV compared with HV
(181.9 [51.7]), no DN (202.3 [25.8]),
and painless DN (216.5 [65.5]); P = 0.04,
x2 = 8.3). Subjects with painful DN
(TTFM 38.4 [3.6]) had the longest tha-
lamic TTFM (in seconds) compared with
the other study groups (HV 33.7 [14.9]),
no DN 35.3 [13.2], painless DN 35.9
[13.7]; P = 0.07, x2 = 6.9). Caudate nu-
cleus perfusion markers were not signiﬁ-
cantly different between groups.
CONCLUSIONS—Painful DN is the
most distressing complication of diabetes
(11), but unfortunately current treat-
ments are often ineffective (12). This
may be as a result of our poor understand-
ing of the pathophysiological processes
involved (13). Using established MR per-
fusion techniques, we demonstrated in-
creased thalamic vascularity (increased
rCBV) with sluggish ﬂow (prolonged
TTFM) in painful DN, possibly reﬂecting
underlying vasodilatation. Delay in bolus
arrival time in both neuropathy sub-
groups reﬂects the burden of underlying
vascular disease. Similar perfusion abnor-
malities have been described in the sural
nerve (14). Despite this, there remains
clear difference in the perfusion proﬁles
of both painful and painless DN. There
were no signiﬁcant differences in the mi-
crovascular perfusion characteristics of
the caudate nucleus. Unlike the caudate,
the thalamus plays a central role in modu-
lating/processing somatosensory informa-
tion that is relayed to the cerebral cortex (8).
We have previously reported that
preservation of thalamic neuronal func-
tion may be a prerequisite for the percep-
tion of pain in DN (2). Hyperexcitable
thalamic neurons have since been re-
ported to contribute to neuropathic pain
in experimental diabetes (15). Thus tha-
lamic neurons can act as central genera-
tors or ampliﬁers of pain in diabetes. Our
ﬁnding of elevated thalamic perfusion
may be related to increased neuronal ac-
tivity.
Limitations of the current study in-
clude an age spread of several years
between cohorts, and age is a factor in
cerebral hypoperfusion. Paradoxically,
however, subjects with painful DN com-
prised the oldest cohort but possessed the
greatest thalamic rCBV. This would sug-
gest comparative hyperperfusion rather
than hypoperfusion. Interestingly, the
difference in thalamic microvascular per-
fusion between painful and painless DN is
not reﬂected by microvascular disease
burden elsewhere with comparable prev-
alence of minimal retinopathy and ne-
phropathy in both groups.
Our goal was to assess whether tha-
lamic perfusion abnormalities are present
in DN. The data presented here at least
preliminarily support this view. A larger
study with sample sizes of 12 from each of
the four groups would achieve 91%
power to detect signiﬁcant differences
among the groups. Future MR perfusion
studies may lead to identiﬁcation of ob-
jective hemodynamic correlates of painful
DN enabling the targeting of speciﬁc
components of the pain matrix pharma-
cologically, hopefully resulting in the de-
velopment of more effective and better
tolerated drugs.
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